FibroBiologics Financials - Benzinga

SPY765.80+0.02%QQQ737.05+0.07%BTC/USD83,254.33−0.24%DIA514.14+0.02%GLD378.31+0.11%TLT78.69+0.09%

FibroBiologics Inc

FBLGNASDAQ

Trade with Public

Trade with Public

$1.36

-0.03-2.16%

At close: Sep 28, 5:00 PM EST

$1.34

-0.02-1.47%

After Hours: 6:06 PM EST

Overview News Earnings Forecast Events Price TargetsFinancialsSentiment Ownership Compare Stock Report

FibroBiologics Financials

FibroBiologics (FBLG) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
FibroBiologics, Inc. - Common Stock Q2 EPS $(0.66) Beats $(0.72) Estimate

FibroBiologics, Inc. - Common Stock (NASDAQ:FBLG) reported quarterly losses of $(0.66) per share which beat the analyst consensus estimate of $(0.72) by 8.33 percent. This is a 72.5 percent increase over losses of

Benzinga Newsdesk

PRO
FibroBiologics, Inc. - Common Stock Q1 EPS $(1.33), Inline

Benzinga Newsdesk

PRO
FibroBiologics, Inc. - Common Stock Q4 EPS $(0.03) Beats $(0.09) Estimate

FibroBiologics, Inc. - Common Stock (NASDAQ:FBLG) reported quarterly losses of $(0.03) per share which beat the analyst consensus estimate of $(0.09) by 67.39 percent. This is a 66.67 percent increase over losses of

Benzinga Newsdesk

PRO
FibroBiologics, Inc. - Common Stock Q3 EPS $(0.13) Misses $(0.11) Estimate

FibroBiologics, Inc. - Common Stock (NASDAQ:FBLG) reported quarterly losses of $(0.13) per share which missed the analyst consensus estimate of $(0.11) by 21.5 percent. This is a 1200 percent decrease over losses of

Benzinga Newsdesk

PRO
FibroBiologics, Inc. - Common Stock Q2 EPS $(0.12) Misses $(0.11) Estimate

FibroBiologics, Inc. - Common Stock (NASDAQ:FBLG) reported quarterly losses of $(0.12) per share which missed the analyst consensus estimate of $(0.11) by 9.09 percent. This is a 500 percent decrease over earnings of

Benzinga Newsdesk

PRO
FibroBiologics H1 2025 Net Loss ~$9.6M

Benzinga Newsdesk